<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="3945">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03055559</url>
  </required_header>
  <id_info>
    <org_study_id>Not identified</org_study_id>
    <nct_id>NCT03055559</nct_id>
  </id_info>
  <brief_title>Trial Protocol GlobiFer - Oral Iron Repletion</brief_title>
  <acronym>TPG</acronym>
  <official_title>Oral Iron Repletion With Globifer Forte® After 12 Weeks of Treatment</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Gedeon Richter Slovakia, s.r.o.</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Gedeon Richter Slovakia, s.r.o.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The haemoglobin level of the patients with iron deficiency should be increased clinical
      relevant after 12 weeks treatment with GlobiFer Forte.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>June 2016</start_date>
  <completion_date type="Anticipated">March 2017</completion_date>
  <primary_completion_date type="Anticipated">March 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>No masking</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of patients with a clinical relevant increase of the haemoglobin level treatment with GlobiFer Forte</measure>
    <time_frame>12 weeks</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Iron Deficiency</condition>
  <arm_group>
    <arm_group_label>Globifer Forte</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Globifer Forte</intervention_name>
    <arm_group_label>Globifer Forte</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. ≥ 18 ≤ 60 years of age

          2. Signed written informed consent

          3. Hb ≥ 8 ≤ 10g/dl for

          4. Female

        Exclusion Criteria:

          1. History of acquired iron overload, known haemochromatosis or first relatives with
             haemochromatosis, and allergic disorders (asthma, eczema, and anaphylactic
             reactions).

          2. Known hypersensitivity to oral iron preparations.

          3. Diseases, which an iron supplementation is not allowed or contraindicated.

          4. Patients on current oral or intravenous iron supplementation

          5. History of erythropoietin therapy in previous 30 days or scheduled for erythropoietin
             therapy or blood transfusion during duration of the study.

          6. Patients who have had iron supplementation within the last 30 days.

          7. Other reasons which in the investigator's judgment argue against inclusion of the
             patient into the trial.

          8. Inability to comprehend study protocol

          9. Participation in another clinical trial (currently or within the last 30 days)
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ján Danko, PhD.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Comenius University's Jessenius Faculty of Medicine</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Veronika Horvath</last_name>
    <phone>+36-20-419-27-78</phone>
  </overall_contact>
  <location>
    <facility>
      <name>Prof. MUDr. Ján Danko, PhD.</name>
      <address>
        <city>Martin</city>
        <zip>036 01</zip>
        <country>Slovakia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Slovakia</country>
  </location_countries>
  <verification_date>February 2017</verification_date>
  <lastchanged_date>February 14, 2017</lastchanged_date>
  <firstreceived_date>February 14, 2017</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Iron, Hemoglobin, Feritin, erytrocyty. transferin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Anemia, Iron-Deficiency</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
